BioCorRx Inc. (OTC: BICX), a developer and provider of innovative treatment support programs for substance use disorders, announced on September 10, 2026, the appointment of Richard J. Baum to its Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
Baum brings nearly three decades of experience in national drug policy, addiction, public health, law enforcement, and justice policy. During 28 years at ONDCP, he served across six presidential administrations and helped shape federal responses to evolving drug threats, including the opioid crisis. His experience spans treatment and recovery policy, prevention, public safety, interagency coordination, and collaboration with state and local partners.
BioCorRx expects to draw on Baum’s policy and systems-level expertise as the Company advances its treatment and pharmaceutical strategies, including LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, the Company’s investigational biodegradable naltrexone implant technology. His perspective will also support the Company’s engagement with treatment and recovery organizations, public health agencies, healthcare systems, justice-system partners, policymakers, and other stakeholders addressing substance use, withdrawal management, and related public health challenges.
“Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx,” said Lourdes Felix, Chief Executive Officer of BioCorRx Inc. “His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care.”
“I am pleased to join BioCorRx as a strategic advisor at a time when the country continues to face significant challenges related to opioid use, addiction treatment, and recovery,” said Richard J. Baum. “BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company’s research evaluating BICX104, an investigational long-duration naltrexone implantable pellet, as a potential treatment for methamphetamine use disorder. I look forward to helping BioCorRx position these approaches within a comprehensive, evidence-based system of care that expands treatment access, supports retention, and improves long-term recovery.”
Baum is a nationally recognized drug policy leader, author, educator, speaker, and strategic advisor. He played a leading role in developing six National Drug Control Strategies. He is an Adjunct Professor at Georgetown University’s McCourt School of Public Policy and the author of Inside America’s Opioid Crisis: 12 Hard Lessons for Today’s Drug War. He also serves on the United Against Fentanyl Board of Directors. His recent writing on the opioid crisis has appeared in The Lancet.
BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Its Beat Addiction Recovery program typically includes proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app and medication prescribed by an independent treating physician. The company also operates UnCraveRx® Weight Loss Program, a medication-assisted weight loss program. For more information, visit www.uncraverx.com and www.BioCorRx.com.
This appointment matters because it signals BioCorRx’s intent to strengthen its strategic positioning amid a persistent opioid crisis and rising methamphetamine use. According to the 2025 National Survey on Drug Use and Health, approximately 4.0 million people in the United States aged 12 or older had an opioid use disorder in the past year, and about 2.7 million reported using methamphetamine in the past year. Baum’s deep policy expertise could help the company navigate regulatory and access barriers, potentially accelerating the adoption of evidence-based treatments like LUCEMYRA and, if approved, BICX104. For an industry grappling with overdose deaths and limited treatment options, this move underscores the growing intersection of drug policy and commercial innovation.
